• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用口服5-氨基酮戊酸的光动力诊断辅助经尿道切除术降低非肌层浸润性膀胱癌反复复发的风险:基于人时法的累积发病率分析

Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.

作者信息

Miyake Makito, Nishimura Nobutaka, Nakai Yasushi, Fujii Tomomi, Owari Takuya, Hori Shunta, Morizawa Yosuke, Gotoh Daisuke, Anai Satoshi, Torimoto Kazumasa, Tanaka Nobumichi, Hirao Yoshihiko, Fujimoto Kiyohide

机构信息

Department of Urology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8522, Japan.

出版信息

Diagnostics (Basel). 2021 Jan 28;11(2):185. doi: 10.3390/diagnostics11020185.

DOI:10.3390/diagnostics11020185
PMID:33525423
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7911613/
Abstract

Clinical evidence regarding risk reduction of repeated bladder recurrence after initial photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT) is still limited in patients with non-muscle-invasive bladder cancer (NMIBC). We analyzed patients with primary NMIBC undergoing TURBT without any adjuvant treatment to compare the risk of cumulative recurrence between the conventional white-light (WL)-TURBT and PDD-TURBT. Out of 430 patients diagnosed with primary NMIBC from 2010 to 2019, 40 undergoing WL-TURBT and 60 undergoing PDD-TURBT were eligible. Multivariate Cox regression analysis for time to the first recurrence demonstrated that PDD assistance was an independent prognostic factor with better outcome ( = 0.038, hazard ratio = 0.39, and 95% confidence interval 0.16-0.95). While no patient experienced more than one recurrence within 1000 postoperative days in the PDD-TURBT group, five out of 40 patients treated by WL-TURBT experienced repeated recurrence. The comparison of cumulative incidence per 10,000 person-days between the two groups revealed that PDD assistance decreased by 6.6 recurrences per 10,000 person-days (exact = 0.011; incidence rate ratio 0.37, Clopper-Pearson confidence interval 0.15-0.82). This is the first study addressing PDD assistance-induced risk reduction of repeated bladder recurrence using the person-time method. Our findings could support clinical decision making, especially on adjuvant therapy after TURBT.

摘要

对于非肌层浸润性膀胱癌(NMIBC)患者,关于初次光动力诊断(PDD)辅助经尿道膀胱肿瘤切除术(TURBT)后降低膀胱复发风险的临床证据仍然有限。我们分析了接受TURBT且未进行任何辅助治疗的原发性NMIBC患者,以比较传统白光(WL)-TURBT和PDD-TURBT之间的累积复发风险。在2010年至2019年诊断为原发性NMIBC的430例患者中,40例接受WL-TURBT,60例接受PDD-TURBT符合条件。对首次复发时间的多因素Cox回归分析表明,PDD辅助是一个独立的预后因素,预后更好(P = 0.038,风险比 = 0.39,95%置信区间0.16 - 0.95)。在PDD-TURBT组中,没有患者在术后1000天内经历超过一次复发,而在40例接受WL-TURBT治疗的患者中,有5例经历了反复复发。两组每10000人日累积发病率的比较显示,PDD辅助使每10000人日复发率降低6.6次(确切P = 0.011;发病率比0.37,Clopper-Pearson置信区间0.15 - 0.82)。这是第一项使用人时法探讨PDD辅助降低膀胱反复复发风险的研究。我们的研究结果可为临床决策提供支持,尤其是在TURBT后的辅助治疗方面。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/d9515f358b76/diagnostics-11-00185-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/474e06a7fe38/diagnostics-11-00185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/9486621ad2b2/diagnostics-11-00185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/dcd218c90bcf/diagnostics-11-00185-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/d9515f358b76/diagnostics-11-00185-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/474e06a7fe38/diagnostics-11-00185-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/9486621ad2b2/diagnostics-11-00185-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/dcd218c90bcf/diagnostics-11-00185-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5d6/7911613/d9515f358b76/diagnostics-11-00185-g004.jpg

相似文献

1
Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method.使用口服5-氨基酮戊酸的光动力诊断辅助经尿道切除术降低非肌层浸润性膀胱癌反复复发的风险:基于人时法的累积发病率分析
Diagnostics (Basel). 2021 Jan 28;11(2):185. doi: 10.3390/diagnostics11020185.
2
Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).光动力诊断辅助经尿道膀胱肿瘤切除术治疗高危非肌层浸润性膀胱癌可改善膀胱内无复发生存率(BRIGHT研究)。
Int J Urol. 2024 Aug;31(8):906-912. doi: 10.1111/iju.15483. Epub 2024 May 2.
3
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (2nd report): Reduced bladder recurrence after PDD-TURBT.5-氨基酮戊酸光动力诊断膀胱癌的真实世界经验(第 2 报):经 PDD-TURBT 后膀胱癌复发减少。
Photodiagnosis Photodyn Ther. 2022 Jun;38:102757. doi: 10.1016/j.pdpdt.2022.102757. Epub 2022 Feb 11.
4
Risks and benefits of transurethral resection of the bladder tumor using photodynamic diagnosis with oral 5-aminolevulinic acid hydrochloride according to age and history of recurrence in patients with non-muscle invasive bladder cancer.根据年龄和复发史,采用口服盐酸5-氨基酮戊酸光动力诊断法对非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术的风险和益处
Photodiagnosis Photodyn Ther. 2023 Mar;41:103294. doi: 10.1016/j.pdpdt.2023.103294. Epub 2023 Jan 18.
5
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.对于原发性高危非肌层浸润性膀胱癌,白光初始手术与光动力诊断引导下的初始手术在二次经尿道切除的肿瘤学获益方面的差异。
Int J Urol. 2024 Aug;31(8):876-885. doi: 10.1111/iju.15474. Epub 2024 Apr 30.
6
Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.使用5-氨基酮戊酸进行光动力诊断与不进行光动力诊断的经尿道非肌层浸润性膀胱癌切除术后疾病复发的比较评估:一项倾向评分匹配分析。
Int J Clin Oncol. 2024 Feb;29(2):205-212. doi: 10.1007/s10147-023-02447-2. Epub 2023 Dec 19.
7
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): Cost impact of transurethral resection of bladder tumor in Japan.膀胱癌 5-氨基酮戊酸光动力诊断的真实世界经验(第 3 次报告):日本经尿道膀胱肿瘤切除术的成本影响。
Photodiagnosis Photodyn Ther. 2023 Dec;44:103758. doi: 10.1016/j.pdpdt.2023.103758. Epub 2023 Aug 19.
8
Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.光动力诊断辅助经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌对日本医疗经济的影响:一项多中心回顾性队列研究。
Int J Urol. 2023 Dec;30(12):1112-1119. doi: 10.1111/iju.15283. Epub 2023 Aug 22.
9
'Real-life experience': recurrence rate at 3 years with Hexvix photodynamic diagnosis-assisted TURBT compared with good quality white light TURBT in new NMIBC-a prospective controlled study.真实世界经验:Hexvix 光动力诊断辅助 TURBT 与高质量白光 TURBT 治疗新诊断非肌层浸润性膀胱癌的 3 年复发率:一项前瞻性对照研究。
World J Urol. 2017 Dec;35(12):1871-1877. doi: 10.1007/s00345-017-2077-6. Epub 2017 Aug 12.
10
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.首次疑似诊断为中高危非肌层浸润性膀胱癌患者的光动力诊断引导下经尿道膀胱肿瘤切除术:与随机对照试验并行的成本效益分析
Eur Urol Open Sci. 2023 May 31;53:67-77. doi: 10.1016/j.euros.2023.05.003. eCollection 2023 Jul.

引用本文的文献

1
The Circadian Rhythm of Intracellular Protoporphyrin IX Accumulation Through Heme Synthesis Pathway in Bladder Urothelial Cancer Cells Exposed to 5-Aminolevulinic Acid.5-氨基酮戊酸作用下膀胱尿路上皮癌细胞中通过血红素合成途径的细胞内原卟啉IX积累的昼夜节律
Cancers (Basel). 2024 Dec 8;16(23):4112. doi: 10.3390/cancers16234112.
2
Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial.非肌层浸润性膀胱癌经尿道切除术中延长口服盐酸5-氨基酮戊酸至光动力诊断的时间对诊断准确性和安全性的影响:一项单臂多中心III期试验
Int J Clin Oncol. 2025 Jan;30(1):110-120. doi: 10.1007/s10147-024-02638-5. Epub 2024 Oct 7.
3

本文引用的文献

1
Photodynamic Diagnosis-Assisted En Bloc Transurethral Resection of Bladder Tumor for Nonmuscle Invasive Bladder Cancer: Short-Term Oncologic and Functional Outcomes.光动力诊断辅助整块经尿道膀胱肿瘤切除术治疗非肌层浸润性膀胱癌:短期肿瘤学和功能结果。
J Endourol. 2021 Mar;35(3):319-327. doi: 10.1089/end.2020.0371. Epub 2020 Nov 3.
2
A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables.一种新的非肌肉浸润性膀胱癌患者膀胱内复发、疾病进展和癌症特异性死亡的风险分层模型:J-NICE 风险表。
Int J Clin Oncol. 2020 Jul;25(7):1364-1376. doi: 10.1007/s10147-020-01654-5. Epub 2020 Mar 30.
3
Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.使用5-氨基酮戊酸进行光动力诊断与不进行光动力诊断的经尿道非肌层浸润性膀胱癌切除术后疾病复发的比较评估:一项倾向评分匹配分析。
Int J Clin Oncol. 2024 Feb;29(2):205-212. doi: 10.1007/s10147-023-02447-2. Epub 2023 Dec 19.
4
Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.蓝光膀胱镜光动力诊断在原发性非肌层浸润性膀胱癌经尿道切除术中的额外肿瘤学益处:来自经验丰富机构的比较研究。
BJUI Compass. 2023 Jan 13;4(3):305-313. doi: 10.1002/bco2.215. eCollection 2023 May.
5
Effect of Photodynamic Therapy with Chlorin e6 on Canine Tumors.二氢卟吩e6光动力疗法对犬类肿瘤的影响。
Life (Basel). 2022 Dec 14;12(12):2102. doi: 10.3390/life12122102.
6
Poor Prognosis With Intravesical Bacillus Calmette-Guérin History After Photodynamic Diagnosis-assisted Transurethral Resection Using 5-Aminolevulinic Acid.经 5-氨基酮戊酸光动力诊断辅助经尿道切除术治疗后,膀胱卡介苗病史患者的预后不良。
In Vivo. 2022 Nov-Dec;36(6):2952-2959. doi: 10.21873/invivo.13038.
7
Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors.与白光相比,光动力诊断与膀胱肿瘤扩大经尿道切除术后复发率降低相关。
Life (Basel). 2022 Apr 26;12(5):641. doi: 10.3390/life12050641.
8
A prospective, single-arm trial of fluorescent ureteroscopy-assisted thulium-holmium:YAG dual laser ablation for upper urinary tract cancer: Study protocol of the FLUAM trial.一项关于荧光输尿管镜辅助铥-钬:钇铝石榴石双激光消融治疗上尿路癌的前瞻性单臂试验:FLUAM试验研究方案。
Contemp Clin Trials Commun. 2022 Mar 2;26:100902. doi: 10.1016/j.conctc.2022.100902. eCollection 2022 Apr.
Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.
2019 年版日本泌尿器科学会膀胱癌临床实践指南:修订工作立场文件。
Int J Urol. 2020 May;27(5):362-368. doi: 10.1111/iju.14210. Epub 2020 Mar 14.
4
Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score.原发性低级别(TaG1)非肌肉浸润性膀胱癌和低危及中危 EORTC 评分患者的多次复发和疾病进展风险。
PLoS One. 2019 Feb 27;14(2):e0211721. doi: 10.1371/journal.pone.0211721. eCollection 2019.
5
Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study.口服5-氨基酮戊酸介导的光动力诊断联合荧光膀胱镜检查用于非肌层浸润性膀胱癌:一项多中心III期研究。
Int J Urol. 2018 Aug;25(8):723-729. doi: 10.1111/iju.13718. Epub 2018 Jul 12.
6
Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer.多次复发事件的预测:膀胱癌中扩展Cox模型的比较
Am J Epidemiol. 2017 Sep 1;186(5):612-623. doi: 10.1093/aje/kwx133.
7
5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.5-氨基酮戊酸介导的膀胱癌光动力疗法
Int J Urol. 2017 Feb;24(2):97-101. doi: 10.1111/iju.13291.
8
Urinary symptoms following external beam radiotherapy of the prostate: Dose-symptom correlates with multiple-event and event-count models.前列腺体外照射放疗后的泌尿系统症状:剂量-症状与多事件和事件计数模型的相关性
Radiother Oncol. 2015 Nov;117(2):277-82. doi: 10.1016/j.radonc.2015.10.003. Epub 2015 Oct 20.
9
Exploration of risk factors predicting outcomes for primary T1 high-grade bladder cancer and validation of the Spanish Urological Club for Oncological Treatment scoring model: Long-term follow-up experience at a single institute.预测原发性T1期高级别膀胱癌预后的危险因素探索及西班牙肿瘤治疗泌尿外科学会评分模型的验证:单机构长期随访经验
Int J Urol. 2015 Jun;22(6):541-7. doi: 10.1111/iju.12749. Epub 2015 Apr 8.
10
Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study.口服5-氨基酮戊酸介导的光动力诊断联合荧光膀胱镜检查用于非肌层浸润性膀胱癌:一项随机、双盲、多中心II/III期研究。
Photodiagnosis Photodyn Ther. 2015 Jun;12(2):193-200. doi: 10.1016/j.pdpdt.2015.03.008. Epub 2015 Apr 2.